PMID- 25114785
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140812
LR  - 20211021
IS  - 2042-0986 (Print)
IS  - 2042-0994 (Electronic)
IS  - 2042-0986 (Linking)
VI  - 4
IP  - 6
DP  - 2013 Dec
TI  - The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 
      allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a 
      perspective review.
PG  - 246-53
LID - 10.1177/2042098613499791 [doi]
AB  - Carbamazepine is a drug that is widely used for the treatment of epilepsy, 
      trigeminal neuralgia and bipolar disorder. This drug is also known to cause 
      cutaneous adverse drug reactions (cADRs) in up to 10% of patients. The recent 
      progress in pharmacogenetics has revealed that human leukocyte antigen (HLA) 
      genotypes are associated with a susceptibility to the cADRs caused by particular 
      drugs. For carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal 
      necrolysis, very strong associations with HLA-B*15:02 have been found mainly in 
      patients of Southeastern Asian origin. In some countries, prescreening 
      HLA-B*15:02 allele has already been put to practical use as a biomarker to avoid 
      the life-threatening adverse drug reactions. In this review, another risk factor 
      for carbamazepine-induced cADRs is discussed, namely HLA-A*31:01. We compare the 
      strength of the association between HLA-A*31:01 and carbamazepine-induced cADRs 
      based on reports for various ethnic populations; discuss the difference between 
      the HLA-A*31:01 and HLA-B*15:02 biomarkers and the usefulness of prescreening 
      HLA-A*31:01 to detect patients at high risk for carbamazepine-induced cADRs; and 
      refer to points that remain to be resolved.
FAU - Kaniwa, Nahoko
AU  - Kaniwa N
AD  - Senior Researcher, Division of Medicinal Safety Science, National Institute of 
      Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
FAU - Saito, Yoshiro
AU  - Saito Y
AD  - Director, Division of Medicinal Safety Science, National Institute of Health 
      Sciences, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ther Adv Drug Saf
JT  - Therapeutic advances in drug safety
JID - 101549074
PMC - PMC4125310
OTO - NOTNLM
OT  - Biomarker
OT  - HLA genotype
OT  - Stevens-Johnson syndrome
OT  - hypersensitivity syndrome
OT  - toxic epidermal necrolysis
COIS- Conflict of interest statement: We confirm that we have read the journal's 
      position on issues involved in ethical publication and affirm that this report is 
      consistent with those guidelines. None of the authors have any conflict of 
      interest to disclose.
EDAT- 2014/08/13 06:00
MHDA- 2014/08/13 06:01
PMCR- 2013/12/01
CRDT- 2014/08/13 06:00
PHST- 2014/08/13 06:00 [entrez]
PHST- 2014/08/13 06:00 [pubmed]
PHST- 2014/08/13 06:01 [medline]
PHST- 2013/12/01 00:00 [pmc-release]
AID - 10.1177_2042098613499791 [pii]
AID - 10.1177/2042098613499791 [doi]
PST - ppublish
SO  - Ther Adv Drug Saf. 2013 Dec;4(6):246-53. doi: 10.1177/2042098613499791.